PEG & ADCs
- FDA Approved Antibody-Drug Conjugates (ADCs) By 2023
- Summary of Approved HER2 ADCs on The Market & in Clinical Trials
- Antibody–Drug Conjugate Payloads: MMAE & MMAF
- Bispecific Antibody Drug Conjugates (ADCs): Emerging Trends
- Maytansinoids as Payloads of ADCs: DM1, DM4
- ADC Therapies: Current Development & Future Prospects
- Antibody-drug Conjugates for HER2-Positive Gastric Cancer
- c-MET: A Novel Target for Anticancer Therapies
- Development of PD-L1 Antibody Drug Conjugates (ADC)
- Peptide-Drug Conjugate (PDC) VS Immune Stimulating Antibody Conjugate (ISAC)